Natural product-derived therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: Avicularin, a flavonol isolated from Polygonum aviculare, Rhododendron aureum and Taxillus kaempferi, promotes an insulin-sensitized state via up-regulation of its target gene Lin-28, 26/March/2017, 11.00 pm

Natural product-derived Lifespan extension therapy: Genistein, an isoflavone isolated from Soy products, prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 26/March/2017, 6.33 am
March 26, 2017
Natural product-based therapy for ageing-associated diseases: Avicularin, a flavonol isolated from Polygonum aviculare, Rhododendron aureum and Taxillus kaempferi, increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 26/March/2017, 11.24 pm
March 26, 2017
Show all

What we say

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: Avicularin, a flavonol isolated from Polygonum aviculare,Rhododendron aureum and Taxillus kaempferi, promotes an insulin-sensitized state via up-regulation of  its target gene Lin-28

price-300[easy_payment currency=”USD”]


From Significance of the study to Public health relevance

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) diabetic disease results in a number of health complications, including diabetic cardiomyopathy (DCM), diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy; (3) one third of people with diabetes suffer from diabetic kidney disease (DKD); and one third of them will develop kidney failure; (4) Diabetes is going to be one of the top 10 causes of death by 2030; (5) the life-long painful injection/drug treatment is required to treat DM; (6) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, that Avicularin, by increasing the expression of its target geneit may (1) increase the expression of IGF1R, INSR, and IRS2; (2) enhance tissue repair; (3) promote regenerative capacity; (4) promote insulin sensitivity; (5) decrease myocardial infarct size; and (6) inhibit diabetic cardiomyopathy (DCM). 

 

Avicularin induces lin28 expression and promotes insulin sensitivity

Figure 1. Mechanistic insights into how Avicularin functions as an anti-hyperglycemic/cardioprotective agent. Avicularin, by increasing the expression of reprogramming protein Lin-28, IGFIR, INSR, and IRS2, it may promote insulin sensitivity and protect from diabetic cardiomyopathy.


Thus,
 pharmacological formulations encompassing Avicularin or its analogues either alone or in combination with other drugs” may be used to treat DM and DCM.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $ 300#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Avicularin promote insulin-sensitized state?

# Research cooperation

For purchase details, you may reach us at info@genomediscovery.org


References

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan L, Natural product-derived therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: Avicularin, a flavonol isolated from Polygonum aviculare, Rhododendron aureum and Taxillus kaempferi, promotes an insulin-sensitized state via up-regulation of its target gene Lin-28, 26/March/2017, 11.00 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.